Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications.
The company markets an innovative portfolio of solutions including the TetraGraph® and ExSpiron® 2Xi, for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
1999
Served areaWorldwide
HeadquartersUlls väg 41, 75651 Uppsala – Sweden
69,883,985
IPOApril 11, 2017
Stock exchange(s)Nasdaq Stockholm